Bispecific antibodies for cancer therapy: A review
- 1 May 2018
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 185, 122-134
- https://doi.org/10.1016/j.pharmthera.2017.12.002
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExperimental Cell Research, 2011
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trialInternational Journal of Cancer, 2010
- Strategies and challenges for the next generation of therapeutic antibodiesNature Reviews Immunology, 2010
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging AntibodyScience, 2008
- Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II StudyClinical Cancer Research, 2007
- Phase I Trial of the Trifunctional Anti-HER2 × Anti-CD3 Antibody Ertumaxomab in Metastatic Breast CancerClinical Cancer Research, 2006
- Immunotherapy of malignant ascites with trifunctional antibodiesInternational Journal of Cancer, 2005
- Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibodyInternational Journal of Cancer, 2002
- Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)Journal of Histochemistry & Cytochemistry, 2001
- Quantitative Estimation of the Hybridization of Rabbit AntibodiesNature, 1962